Great Debates in Lung Cancer
Integrating the New Paradigm of Immuno-Oncology into Non-Small Cell Lung Cancer Management.
Overview
  • Dates of Release & Expiration: December 20, 2015 - December 20, 2016
  • Available "24/7" on-demand, to be viewed either as a CME or CE or non-accredited program
  • 6 expert medical oncologists
  • 1.5 Category 1 CME credits available for physicians
  • 1.5 CE credits available for nurses and pharmacists
Co-Chairs
Howard "Jack" West, MD
Medical Oncologist
Thoracic Oncology Specialist
Swedish Medical Center
President & CEO of GRACE
Global Resource for Advancing Cancer Education
Seattle, WA

Karen Kelly, MD
Professor of Medicine
Associate Director for Clinical Research
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

 
Click here to
view this 1.5-hour webinar and earn either CME or CE credit. Requires completion of a brief evaluation form, participation in 4 pre- and post-questions, and successfully passing a CME or CE test of 4 questions
 
Click here to
view this 1.5-hour webinar without CME or CE credit
 
 

Overview

The primary objective is to provide the target audience of oncologists, hematologist/oncologists, and other clinicians with knowledge and competence involving immuno-oncology that helps them implement practice performance changes so that they can improve outcome in their NSCLC patients. The symposium addresses the key, clinical and scientific issues facing oncologists and other healthcare professionals treating NSCLC patients with Immuno-Oncology.

Target Audience

The target audience includes medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, Fellows, Physician Assistants, oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied health-care professionals involved in the treatment, care and management of patients with NSCLC. Lung cancer is treated optimally by a multi-disciplinary approach.

Learning Objectives

PHYSICIANS
  1. Analyze the differences in how efficacy is measured when NSCLC treatment is immuno-oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Compare and contrast the differences in Mechanisms of Action between immune therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using immune-therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Evaluate the strategies for determining which NSCLC patients are candidates to receive immuno-oncology therapy versus treatment with traditional targeted or chemotherapy.
NURSES
  1. List the differences in how efficacy is measured when NSCLC treatment is immuno-oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Recall the differences in Mechanisms of Action between immune therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using immune-therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Describe the strategies for determining which NSCLC patients are candidates to receive immuno-oncology therapy versus treatment with traditional targeted or chemotherapy.
PHARMACISTS
  1. List the differences in how efficacy is measured when NSCLC treatment is immuno-oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Recall the differences in Mechanisms of Action between immune therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using immune-therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Describe the strategies for determining which NSCLC patients are candidates to receive immuno-oncology therapy versus treatment with traditional targeted or chemotherapy.

Faculty & Disclosures

Howard "Jack" West, MD (Co-Chair)
Medical Oncologist
Thoracic Oncology Specialist
Swedish Medical Center
President & CEO of GRACE
Global Resource for Advancing Cancer Education
Seattle, WA

Consulting Fees: AstraZeneca, BMS, Genentech/Roche
Fees for Non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): AstraZeneca
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Karen Kelly, MD (Co-Chair)
Professor of Medicine
Associate Director for Clinical Research
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

I have no real or apparent conflicts of interest to report.

Faculty
Mary E.R. O'Brien, MD, FRCP
Consultant Medical Oncologist
The Royal Marsden Hospital
Chair, European Organization for
Research and Treatment of Cancer (EORTC)
Lung Cancer Group
Sutton
UNITED KINGDOM

Consulting Fees: MSD

Hossein Borghaei, DO
Chief, Thoracic Oncology
Director, Lung Cancer Risk Assessment
Fox Chase Comprehensive Cancer Center
Philadelphia, PA

Consulting Fees: BMS, Celgene, Lilly, Clovis and Genentech
Honoraria: BMS, Celgene
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Edward B. Garon, MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Contracted Research: BMS, Merck, Novartis, Pfizer, AstraZeneca, Genentech, Heat
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Charles Rudin, MD, PhD
Medical Oncologist
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Co-Chair Eastern Cooperative Oncology Group
Member, National Cancer Institute
Thoracic Malignancies Steering Committee

Consulting Fees: Celgene, GSK, Boehringer Ingelheim. Merck, Clovis

Joan Schiller, MD
Professor of Medicine
Chief, Division of Hematology-Oncology
University of Texas Southwestern Medical Center
Deputy Director,
Simmons Comprehensive Cancer Center
Dallas, TX

Consulting Fees: Genentech/Roche

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC

I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Steve Madison, RPh, MBA (BMLI Manager)

I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD

I have no real or apparent conflicts of interest to report.

Peer Review Process of Conflicts of Interest

This educational activity has been independently peer-reviewed.

Disclosure of Unlabeled Uses

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.

The Biomedical Learning Institute (BMLI) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.

CME/CE Accreditation & Credit Designation

To receive CME/CE credit participation in the entire activity by viewing the activity and the completion of a brief evaluation form, participation in 4 pre- and post-questions, and successfully passing a CME/CE test of 4 questions.

The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Biomedical Learning Institute designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Biomedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-15-005-H01-P
Credits: 1.5 hours (0.15 ceus)
Type of Activity: Knowledge

The Biomedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.

The Biomedical Learning Institute designates this educational activity for 1.5 contact hours.

Accreditation by the American Nurses Credentialing Center's COA refers to recognition of educational activities and does not imply approval or endorsement of any product.

Participation at the entire activity, a 70% or better score on the post-test and completion of the evaluation form is required to receive CE contact hour credit.

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 1.5 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Educational Support

Sincere appreciation is extended to Bristol-Myers Squibb for their generous support of this educational activity

Educational Needs

Lung cancer is a significant unmet medical need. It is the leading cause of cancer deaths in the US and in many other countries. In 2014, according to the American Cancer Society Facts and Figures there were an estimated 224,210 new cases, and 159,260 deaths from lung cancer. Survival rates vary depending upon the stage of the lung malignancy when it is diagnosed. Globally, the five-year survival rate for Stage I NSCLC is approximately 50 percent. For Stage IV NSCLC, the five-year survival rate is approximately two percent. Thus, it is clear that a significant unmet medical need exists for patients with lung cancer.

Because Immuno-Oncology is so different from traditional systemic therapy for lung cancer, targeted therapy and chemotherapy, a significant educational need exists to help medical oncologists and other healthcare professionals (HCPs) quickly understand how to utilize immunotherapy in their practices to help improve their lung cancer patients’ outcomes today.

Click here for the Computer System Requirements to view this webinar